All Episodes

London based Cytospire Therapeutics has announced an $83M series A financing to develop first-in-class pan-gamma delta T-cell engagers - the lead program is an EGFR targeting solid tumors

Replimune's Chairman discusses FDA's polarizing decision to not approve the company's melanoma treatment after a new review. He says they have filed a FOIA request to learn more about FDA's process

Invivyd develops monoclonal antibodies to prevent or treat infectious diseases. This approach could be useful in tamping down the measles outbreaks that have been occurring due to under-vaccination

Bay Area based Epia Neuro exited stealth earlier this month with the goal of developing a device implanted in the skull that could act as an interface to a glove to helps stroke survivors regain grip

Peter Hotez discusses tropical disease, the importance of science communication, career advice for young scientists, and more

Physican and Biotech Investor Adam May reacts to this morning's 52 week Rezpeg data in alopecia from Nektar

10x Genomics today is announcing Atera, its new in situ spatial transcriptomics platform

Is this analyst the world's biggest bear on the weight loss space? After downgrading Lilly to a sell rating, HSBC's Rajesh Kumar discusses why he thinks pricing factors are being under-appreciated

Raymond James Biotech Innovation Symposium: Biotech analyst Tiago Fauth shares his read on the mood of investors and discusses companies he covers

Raymond James Biotech Innovation Symposium: Korro Bio CEO Ram Aiyer discussed how the company has chosen new RNA editing programs to move forward with this year

Raymond James Biotech Innovation Symposium: Dyne's CEO John Cox shares an overview of the company's recent landmark DMD data

Raymond James Biotech Innovation Summit: Checking in with Vera's Founder & CEO Marshall Fordyce ahead of the July 7 FDA decision date for the APRIL & BAFF targeting IgAN treatment Atacicept

Raymond James Biotech Innovation Symposium: Akebia's CEO John Butler shares an update on the launch of Vafseo and discusses two of the company's pipeline programs

Raymond James Biotech Innovation Symposium: Wave Life Sciences CEO Paul Bolno discusses the recent INHBE data and previews alpha-1 antitrypsin deficiency data being presented next month

Raymond James Biotech Innovation Symposium: Tectonic Therapeutic develops biologics against GPCR targets - and is making headway on an unmet need for pulmonary hypertension in heart failure patients

Raymond James Biotech Innovation Symposium: Eupraxia has a novel extended release platform for - with data already out and more on the way later this year, Eosinophilic Esophagitis has been a good PoC

Raymond James Biotech Innovation Symposium: Septerna is developing oral small molecules that target GPCRs, it now has two programs in the clinic

Raymond James Biotech Innovation Symposium: Raymond James analyst Chris Raymond shares his take on biotech and companies he covers

Harbinger Health is announcing its emphasis on a new category of cancer screening tests today, RESOLVE, that are meant to be used upon the suspicion of cancer symptoms to speed diagnosis and treatment

Spyre Therapeutics announced today that SPY001, an extended half-life α4β7, showed a 40% clinical remission rate at 12 weeks in moderate-to-severe UC

Alloy Therapeutics announced a deal with Biogen today to help them discover antisense therapeutics using Alloy's ASO platform. Alloy Founder & CEO Errik Anderson fills us in at the company's R&D Day.

The new CEO of Stoke Therapeutics, Ian Smith, discusses Stoke Therapeutics' Dravet syndrome therapy, which caught much attention after publishing phase 1/2 data in NEJM last month

Iambic's CEO Tom Miller discusses the company's approach to AI drug discovery (hint: it's way more than protein folding), and highlights the company's clinical HER2 program, and two others on the way

Already this year Chai Discovery has raised a $130M series B and struck a discovery partnership with Eli Lilly - Co-Founder Jack Dent describes how Chai is using AI to design antibodies

CellCentric has kicked off dosing of its first registration-supporting study for the oral p300/CBP inhibitor inobrodib in multiple myeloma today

Solid Biosciences CEO Bo Cumo discusses recent DMD data for the company's microdystrophin gene therapy, and explains the development and regulatory steps ahead

Christian Tidona's BioMed X and Michal Preminger are launching BioMed X Venture Labs in Cambridge, MA to create 'build to solve' startups with partners

Apogee Therapeutics' CEO Michael Henderson discusses today's 52 week maintenance data for the company's extended-dose IL-13 inhibitor it atopic dermatitis

Biotech CEOs discuss the importance of culture, getting through challenging times, their policy wishlist, and how they are proud of the ways our industry gives back

From London: Yellowstone Biosciences is leveraging an Oxford AML patient biobank to develop an HLA Class II platform of T-cell engagers

From London: Edward Hodgkin is the Executive Chair of Syncona's 'Slingshot', a platform that takes early stage science from academic labs that isn't ready to be a company and helps matures it

From London: Purespring Therapeutics is developing a gene therapy that is delivered locally to the podocytes in the kidney and aims to treat IgAN as its initial indication

From London: Resolution Therapeutics is in the clinic with its engineered regenerative macrophage therapy to treat end stage liver disease

From London: With science from the Francis Crick Institute, ALTx Therapeutics launched with £12.55m last month to target cancers that rely on the Alternative Lengthening of Telomeres (ALT)

From London: iOnctura is developing its allosteric PI3Kδ for uveal melanoma - an indication that has seen progress but still has much unmet need

From London: Spur Therapeutics is an a phase 3 for its gene therapy for Gaucher Disease - using a unique construct that allows them to have a lower dose than other gene therapies

From London: Beacon Therapeutics has a phase 3 trial scheduled to read this year for its gene therapy for X-Linked Retinitis Pigmentosa (XLRP)

From London: Syncona CEO Chris Hollowood discusses the firm's public and private funds, and the state of investing in life sciences today from the firm's Capital Markets Day

Checking in with Menlo Ventures' Partner Greg Yap to get his take on the latest trends in AI in healthcare

Earli, which raised $105M in two rounds, is developing 'Cancer-Activated Promoters' that are set off by cancer-specific transcription factors and turn tumor cells into therapeutic payload factories

Barclays Miami: MannKind CEO Michael Castagna shares an update on the company, including a recent $360M acquisition, and two regulatory reviews at FDA that have decision dates over the coming months

Barclays Miami: Barclays' Senior Biotech Analyst Etzer Darout shares his take on biotech and discusses companies he covers that have been in the news

Barclays Miami: Zealand Pharma CEO Adam Steensberg makes the case for last week's amylin data

Barclays Miami: Barclays' Head of Healthcare M&A shares his take on the current environment of dealmaking

Reunion Neuroscience recently received Breakthrough Therapy Designation from FDA for its psychedelic based treatment for postpartum depression (PPD)

Barclays Miami: Ocular Therapeutix's Chair Pravin Dugel discusses feedback he has been receiving on SOL-1 since announcing it last month

Barclays Miami: Xencor CEO Bassil Dahiyat discusses the company's internal pipeline and how bi-specifics and other modalities are engineered to be increasingly sophisticated and more precise

Barclays Miami: Recludix believes the time is right in science to drug SH2 domains. The company's lead programs target STAT6 and BTK

Barclays Miami: Barclays' Senior Biotech Analyst Ellie Merle shares her take on biotech and thoughts on companies she covers that have been in the news

Barclays Miami: Janux's Founder & CEO David Campbell shares his thoughts on the company's PSMA x CD3 masked T-cell engager and discusses next steps. Plus, a CD19 for autoimmune

Barclays Miami: Teva CEO Richard Francis talks about the company's emphasis on developing innovative medicines - including two recent financial deals to speed up development of IL-15 and TL1A

Barclays Miami: Latigo Bio aims to have a best-in-class Nav1.8 - a new class of medicines for pain that is the biotech sector's answer to the challenges that are presented by opioids

Barclays Miami: Arvinas will have an update next week for its LRRK2 targeting PROTAC for Parkinson's. The new CEO previews that and talks other targets they are working on

Barclays Miami: Electra Therapeutics has taken a novel approach to target Signal Regulatory Proteins (SIRPs). It's in a pivotal for its first indication right now

Barclays Miami: enGene is looking to have pivotal data and to file for its non-viral delivered gene therapy for bladder cancer this year

Barclays Miami: Barclays' Chair and Co-Head of Global Biopharma Investment Banking Jim Birchenough shares his take on the sector, M&A, and the IPO environment

Quell Tx believes that restoring immune balance rather than entirely depleting immune cells is key for many autoimmune conditions - its CAR-Treg initiated a phase 1/2 in RA & Systemic Sclerosis today

Protagonist Therapeutics has two medicines in front of FDA right now - we discuss the expertise in peptide based drug development that has enabled them to get to this point

Cambridge, UK based Arecor uses formulation and development expertise to improve the profile of medicines - leveraging this, the company believes it has its own best in class insulin

NewLimit is using epigenetic reprogramming to bring cells back to a younger and healthier state, thus tackling age related disease

Gordian Biotechnology announced that it will be using its unique large-scale in vivo screening process to help Pfizer look for new targets against obesity

Cambridge, UK based Microbiotica announced results from a phase 1b trial of its microbiome treatment MB310 in ulcerative colitis showing a 63% remission rate

Ocular Therapeutix Chair & CEO Pravin Dugel discusses the result of today's SOL-1 phase 3 superiority trial of AXPAXLI vs EYLEA in wet AMD

Oxford based Infinitopes raised an additional $15.4M in a second closing of its seed round to bring the total raised to $35.1M. It will have clinical data on its cancer vaccine by the end of the year

From Oxford: Carlo Rinaldi's team has received two grants from Oxford-Harrington Rare Disease Centre to develop treatments for Spinal-bulbar muscular atrophy (SBMA) and Friedreich's ataxia

From Oxford: Professor Matthew Wood describes the Oxford-Harrington Rare Disease Centre, a transatlantic effort to accelerate drug development for rare diseases

Biotech CEOs discuss the state of the industry, what is needed to compete globally, the importance of having a patient-centric approach, and more

Analyst Thursdays: Mizuho Senior Biotech Analyst Graig Suvannavejh shares his take on three key biotech trials that are scheduled to read out soon, and one that recently happened

Upstream Bio's CEO Rand Sutherland discusses today's severe asthma data for verekitug, a TSLP receptor antagonist

Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib

Analysts Thursdays: Clear Street Senior Biotech Analyst Kaveri Pohlman shares her take on biotech for 2026 and discusses her top picks

SF Healthcare Week: Perceptive Advisors' Joe Edelman, one of the top investors in biotech, shares his investment philosophy and his take on the sector heading into 2026

SF Healthcare Week: Cytokinetics CEO Robert Blum discusses the approval and impending launch of the cardiomyopathy therapy MYQORZO

SF Healthcare Week: Sana Bio's CEO Steve Harr describes the science behind the company's cell therapy program that aims to be a cure for type 1 diabetes

SF Healthcare Week: Alumis' CEO Martin Babler walks us through the two successful phase 3 trials the company announced for its TYK2 last week

SF Healthcare Week: CEO Heather Turner tells us about the neuropsychiatric diseases medicine that enabled LB Pharma to IPO in a tough market last year

SF Healthcare Week: Neurocrine Biosciences CEO Kyle Gano describes how the company's novel muscarinic agonist portfolio is rooted in novel drug design, with its lead M4 agonist in late-stage trials

SF Healthcare Week: Recursion's new CEO Najat Khan shares her vision for the company and for AI in biotech

SF Healthcare Week: Wave Life Sciences CEO Paul Bolno discusses the company's INHBE obesity program, AATD, PNPLA3, and more

SF Healthcare Week: Roivant CEO Matt Gline provides an update on the 'vant ecosystem

SF Healthcare Week: Astellas Pharma CEO Naoki Okamura describes the type of assets the company looks for externally, and covers key internal pipeline assets

SF Healthcare Week: Soleno Therapeutics' Chairman & CEO Anish Bhatnager discusses the launch of its Prader-Willi syndrome therapy VYKAT XR

SF Healthcare Week: Madrigal CEO Bill Sibold talks about the commercialization of the MASH treatment Rezdiffra, and two bolt on deals the company has done for combinations

SF Healthcare Week: Insmed CEO Will Lewis discusses the launch BRINSUPRI and pipeline readouts ahead in 2026

SF Healthcare Week: Beam's CEO John Evans shares an update on based editing for alpha-1 antitrypsin deficiency, sickle cell disease, and more

SF Healthcare Week: Flagship Pioneering's Founder Noubar Afeyan shares his thoughts on the image of science in the United States today, biotech's roller coaster 2025, mRNA, AI, and more

SF Healthcare Week: Baird Senior Analyst Brian Skorney comments on Monday's conference news and highlights his top picks ahead for 2026

SF Healthcare Week: Vera Therapeutics’ announced this week that the FDA accepted the company’s filing for atacicept, a potential new treatment for IgA Nephropathy

SF Healthcare Week: Biohaven's Chairman & CEO Vlad Coric shares updates on the company's pipeline in immunology, obesity, and epilepsy

SF Healthcare Week: Abivax CEO Marc de Garidel reflects on a breakout 2025 for obefazimod and key data that will read out this year

Mizuho Senior Biotech Analyst Salim Syed highlights key companies in the news he covers heading into the new year

William Blair Senior Biotech Analyst Andy Hsieh shares an overview of the obesity space heading into 2026

A deep dive discussion on Abivax with Truist Senior Biotech Analyst Gregory Renza

ASH 2025: Kelonia Therapeutics presented convincing late-breaking data at ASH today from its initial patients in multiple myeloma suggesting that in vivo CAR-T is on track to be a next innovation

ASH 2025: MaaT Pharma's microbiome based treatment for refractory GVHD is in front of EMA right now for a possible 2026 approval - the pivotal data was presented in an oral at ASH this week

ASH 2025: Ascentage Pharma Chairman & CEO Dajun Yang shares an update on the company's Bcl-2, lisaftcoclax, which was recently approved in China and is in multiple global registration studies

ASH 2025: Corvus CEO Richard Miller believes that ITK inhibitors can have the same broad impact on T-cell diseases as BTK inhibitors have had on B-cell diseases - he would know

ASH 2025: Nurix CEO Arthur Sands discusses his company's BTK degrader data at ASH, and highlights the benefits of degraders more broadly in oncology and I&I

ASH 2025: Cullinan Therapeutics CEO Nadim Ahmed highlights the company's FLT3xCD3 bispecific T-cell engager data at ASH in AML and MDS

ASH 2025: Kura Oncology CEO Troy Wilson discusses the recent approval of the company's menin inhibitor (KOMZIFTI) in R/R NPM1 mutated AML, and highlights ASH data in the front line setting

ASH 2025: Aleta Biotherapeutics' Paul Rennert shares the company's first clinical data for its CAR-T cell engager program that is meant to increase the density of CD19 on B-cell malignancies.

ASH 2025: March Biosciences reported 5 complete responses in all 5 first patients treated in the phase 2 study of its CD5 targeting CAR-T for T-cell lymphoma

Lyell Immunopharma CEO Lynn Seely discusses her company's CD19/CD20 dual antigen CAR-T data at ASH

ASH 2025: Rigel's CEO Raul Rodriguez discusses the company's IRAK1/4 data in patients with lower-risk MDS

ASH 2025: CEO Will West describes how CellCentric is seeing results for its oral p300/CBP inhibitor, Inobrodib, in heavily refractory multiple myeloma patients

ASH 2025: Disc Medicine CEO John Quisel walks us through the RALLY-MF Phase 2 trial data of DISC-0974 in anemia of myelofibrosis

ASH 2025: Orca Bio has an April 6th PDUFA date from FDA for its cell therapy product, Orca-T, that aims to solve the problem of treatment-related toxicities that come with stem cell transplants

ASH 2025: Kite Pharma EVP Cindy Perettie discusses today's new data for the pivotal IMMagine-1 study of the BCMA CAR-T, anito-cell. Plus, the future of dual antigen and in vivo CAR-Ts.

ASH 2025: Von Willibrand disease is the most common bleeding disorder, though many people have never heard of it. Star Therapeutics is working on a solution that is already in phase 3

ASH 2025: Legend Biotech CEO Ying Huang discusses new long-term Carvykti data, looming competition, a CD19+CD20 γδ program, and in vivo CAR-T

From London: Cancer Research Horizons takes research from Cancer Research UK (and beyond) and invests in the translational work and companies that turn it into cures

Jefferies London: Ipsen has done a string of deals over recent years, including acquiring ImCheck last month. CEO David Loew says the company has billions in firepower to do more

Jefferies London: Terns' CEO Amy Burroughs previews the company's upcoming ASH presentation for the allosteric BCR::ABL1 inhibitor tern-701 in relapsed/refractory cml

Jefferies London: Affinity Asset Advisors' Patrick Nosker shares a public investor's perspective on biotech and walks us through a few of his firm's top positions

Jefferies London: Medicxi Announced a €500 Million Fund V ahead of this week's conference - Co-founder Giovanni Mariggi describes the firm's asset-centric approach to investing in biotech

Jefferies London: Olema Oncology more than doubled yesterday when Roche announced surprise data for its oral SERD - the CEO reacts and shares the development program for Olema's competing asset

Jefferies London: Zealand Pharma CEO Adam Steensberg believes that amylins will overtake GLPs as the backbones of obesity treatments in the future

Jefferies London: Nanobiotix has a new platform that is meant to help RNA/DNA-based therapies, gene therapies, oncolytic viruses and other liver-delivered medicines have better efficacy

Jefferies London: Jefferies Global Chairman of Healthcare Philip Ross discusses the environment for biotech and deals

Jefferies London: Chief Scientific Officer Tony Wood covers the latest highlights in GSK's pipeline, including oncology, respiratory, and inflammation

Jefferies London: Zymeworks had double-news during London Life Science Week - a P3 success for its HER2 bispecific in gastroesophageal cancer and it also launched a new royalty model

Jefferies London: Protagonist Therapeutics CEO Dinesh Patel responds to takeout speculation and discusses the company's programs and culture of partnering

Jefferies London: BeOne Medicines announced a phase 3 success for its HER2 bispecific today in gastric cancer. John Olyer walks us through that and the whole pipeline

Jefferies London: Sofinnova Partners announced a new $750M fund XI today that will invest in early stage companies in biotech

Jefferies London: Jefferies M&A Banker Chris Roop shares his take on the environment for deals in biotech

Legend Biotech CEO Ying Huang shares a post-earnings update from the company's new R&D Center in Philadelphia

Apogee will have at lest four key trial readouts for its half-life optimized IL-13 program next year, including monotherapy trials and in combination with OX40L and TSLP.

Avalo Therapeutics is developing a high affinity IL-1β for hidradenitis suppurativa - key phase 2 data will come next year

Stifel's Head of Global Equity Capital Markets Seth Rubin describes the investor feedback he is hearing about the sector lately and the fundraising environment for companies

Sionna Therapeutics is trying to improve the treatment paradigm for cystic fibrosis by targeting NBD1, a nucleotide binding-domain of the CFTR protein, and restore healthy function for all

Stifel's I&I expert Alex Thompson shares his take on the environment and discusses names he covers that have key catalyst events

Celcuity release what it believes is practice changing breast cancer data with its multi-target PAM inhibitor. Co-Founder & CEO Brian Sullivan describes why he believes the data is so important

Spyre Therapeutics is developing a basket of therapies (α4β7, TL1A, and IL-23) that are meant to have a greater half-life and work better in combination that current therapies for IBD and rheumatology

Vicore Pharma is leveraging in understanding the Renin-Angiotensin System (RAS) to develop angiotensin II type 2 receptor agonists for IPF and beyond

The early part of 2026 is going to be a key time for REGENXBIO's gene therapies, with an FDA decision date schedule for Hunter's Syndrome and a pivotal trial readout in DMD

Aardvark Therapeutics' approach to obesity is to inhibit hunger (vs appetite). It has a key pivotal trial scheduled to read in Prader-Willi syndrome early next year, and is also working on weight loss

Stifel's Head of Therapeutics Paul Matteis shares his take on the sector and discusses names he covers that have key catalyst events

Upstream Bio is focused on the TSLP space, and has a unique approach of targeting the receptor as opposed to the ligand. It might give them a better dosing and efficacy profile.

Adaptyx announced $14M in additional seed financing to fund the development of a continuous health monitoring device that aims to track small molecules, electrolytes, hormones, drugs, and proteins

Aulos Bioscience presented phase 2 data at SITC for its antibody that binds to IL-2 and prevents CD25 binding - showing responses in melanoma and lung

Enara Bio publicly announced its first cancer specific 'dark genome antigen' target at SITC - DARKFOX, an alternative open reading frame associated with FOXM1

Compugen is standing firm on its belief that TIGIT will ultimately succeed with Fc reduced/silent constructs

Synthekine presented data at SITC on its α/β-IL-2 receptor biased partial agonist showing a 53% response rate in PD-L1 negative nonsquamous NSCLC

Marengo Therapeutics has presented data at ESMO and SITC showing that its lead program, which is designed to activate Vβ6/10 T cells, is active in multiple tumor types

Brain shuttle technologies have been in the news a lot lately. Natalie Ricciardi explains what you need to know about 1st and 2nd generation technologies in development.

Menlo Ventures published a report showing that the healthcare industry is the leading adopter of AI - one of the co-authors shares the key takeaways

BIO-Europe 2025: Spain based ARTHEx Biotech is a European player in the DM1 space, and believes its microRNA strategy offers a dual benefit that it says is unique to the field

BIO-Europe 2025: Sparrow Pharmaceuticals raised a $95M series B last month - it will be testing its cortisol depleting HSD1 inhibitor in type 2 diabetes

BIO-Europe 2025: Topas Therapeutics is delivering nanoparticles to the liver to establish tolerance in T-cells for autoimmune and immune-mediated disease - it recently had intriguing data in celiac

BIO-Europe 2025: Step Pharma has 'followed the genetics' to be the first company to target CTPS1 inhibition for cancer - CEO Andrew Parker walks us through this unique science

BIO-Europe 2025: Barcelona based Connecta Therapeutics is moving its neuroplasticity modulator for fragile X syndrome into a phase 2a study after completing first in human studies late last year

BIO-Europe 2025: Switzerland based ReproNovo is focused on reproductive health - with two clinical stage assets and three indications it is going after

BIO-Europe 2025: Anavo Therapeutics is focused on phosphatases - and is publicly talking about its two lead programs for the first time

BIO-Europe 2025: Herantis Pharma is developing HER-096 for Parkinson's, a blood-brain-barrier penetrant small peptide molecule that is designed to mimic the activity of CDNF

BIO-Europe 2025: Valneva's partner Pfizer has been running a big trial of a Lyme disease vaccine that has covered the last three seasons - it will read out in the first part of next year

Roche will pay Manifold Bio $55M up front, and up to $2B in biobucks, to collaborate on multiple next-generation brain shuttles for neurological diseases

BIO-Europe 2025: ReNewVax CEO Neil Murray believes the antigens the company has found will enable it to develop a pneumococcal vaccine that targets all ca.100 existing variants

BIO-Europe 2025: Abivax CEO Marc de Garidel discusses physician and payor feedback after obefazimod's phase 3 UC induction readouts, and next steps regarding maintenance and Crohn's

BIO-Europe 2025: AAVantgarde Bio, which is working on gene therapies for inherited retinal diseases that are caused by mutations in large genes, closed a $141M series B raise today

Mathai Mammen recaps the first clinical data Parabilis Medicines reported on its beta-catenin program earlier this month at EMSO and AACR-NCI-EORTC 2025. Plus, degraders for prostate cancer, and more.

BiotechTV visited South San Francisco based Noetik and saw how they are digitizing tumor samples and using AI to sort through the complexity of the biology for drug discovery

Sonoma Biotherapeutics announced early clinical data today in a late-breaker at #ACR25 for its CAR-Treg to treat rheumatoid arthritis. Co-Founders Jeff Bluestone and Fred Ramsdell walk us through it.

Zag Bio launched today with $80M, and aims to tackle autoimmune disease by using antibodies to reprogram how Tregs and Teffs are created in the thymus. The lead indication will be Type 1 diabetes

Hemab Therapeutics, a company specializing in developing treatments for bleeding disorders, announced a $157 million series C raise today. CEO Benny Sorensen describes the work and unmet need.

Weave Bio, which raised a $20M series A this month, is aiming to use software and LLMs to automate and streamline regulatory submissions for drug development

Ahead of a year of increased clinical activity, Entrada Therapeutics' CEO Dipal Doshi discusses the company's EEV platform, DMD programs, and a Vertex partnership in DM1

Disc Medicine CEO John Quisel describes the process of becoming among the first companies to receive FDA's new Commissioner's National Priority Voucher (CNPV)

Biotech entrepreneurs share advice on navigating through today's uncertain times: "It's going to be okay"

Flagship Pioneering announced its newest company to emerge out of stealth mode today: Expedition Medicines. It is leveraging generative design for small molecule covalent chemistry

Biotech veteran Oz Azam has become the CEO of Cue Biopharma. He walks us through the science behind the company's new focus in autoimmune that has him excited about the opportunity

Get to know Women In Bio, and how this organization helps women at all stages of their careers in biotech

Emeryville, CA based Profusa is developing an injectable biosensor that aims to generate biochemistry information for users in real time

PepGen's CEO James McArthur gives an overview of the company's recent data in myotonic dystrophy type 1, which showed a mean splicing correction of 53.7% at the 15 mg/kg dose

Benchtalk 2025: Kate Haviland discusses the $9B+ acquisition of Blueprint by Sanofi, being chair of Fulcrum, her thoughts on M&A, and what is interesting in biotech today

Benchtalk 2025: Generate:Biomedicines' VP of Informatics Stephen Kottmann describes the investments in technology that ensures only the highest quality data returns back into its models

Benchtalk 2025: Benchling Co-Founder & CEO Sajith Wickramasekara describes why he believes science and Benchling are entering a new era of speed and cost of R&D

Benchtalk 2025: Dyne Therapeutics' CSO Ron Batra describes the company's FORCE platform, and previews big trial scheduled in DMD and DM1 over the next year

Sunrise Group, which has designed a mandibular sensor for at-home diagnosis of sleep apnea, recently raised $29M to expand its digital sleep clinic that patients can access remotely

Oxford's OrganOx became one of the UK's biggest news stories when it was announced it would be acquired by Japan's Terumo for approximately $1.5 billion - here's the revolutionary technology behind it

Oxford, UK based OMass Therapeutics, experts in the use of mass spectrometry in drug development, recently landed a $20M up front licensing deal with Roche on one of its preclinical candidates for IBF

NYSE Market Strategist Eric Criscuolo discusses biotech's newfound momentum and whether it might attract generalists to take a look at the sector

Immuneering's CEO walks us through the company's MEK data in pancreatic cancer, and explains the science behind 'deep cyclic inhibition'

R.W. Baird Managing Director & Senior Biotech Analyst Brian Skorney discusses numerous battleground companies in biotech

Biotech veteran David Hung talks about the launch of IBTROZI in ROS1 positive non-small cell lung cancer, and what's next for Nuvation Bio

Complement Therapeutics received IND clearance from U.S. FDA today to start a trial of its AAV gene therapy for geographic atrophy that delivers a truncated version of Complement Receptor 1 to the eye

Align Summit: Cambridge based Quiver Bioscience is developing ASOs for CNS conditions, including having programs in the red hot Nav1.7/1.8 pain space

Align Summit: Toronto based HDAX Therapeutics believes there are many indications to tackle with its dual binding approach to HDAC6

Align Summit: Allston based KiraGen Bio is aiming to program CAR-T cells to tune out the suppressive nature of the tumor micro environment. The first program will be for GBM.

Soufflé Therapeutics exited stealth today with the goal of developing nucleic acid therapies, like siRNAs and ASOs, delivered to any cell in the body by targeting internalizing receptors

Brian Alexander, former CEO of Foundation Medicine, describes how Valo Health is using its AI expertise to partner with companies and foundations on discovery and development projects

Aerska launched in the UK today with $21M in financing to develop RNAi medicines for neurological conditions that are delivered to the brain via 'brain shuttle' technologies across the BBB

Enanta Pharmaceuticals' CEO and CMO discuss data announced today on the company's RSV treatment, Zelicapavir, and describe the road ahead for this program and the company

Sunny Kumar, a partner at Informed Ventures, and an active investor in the AI space, talks about current and future implications of AI's impact on healthcare

Eko Health's Co-Founder & CEO shows BiotechTV the company's digital stethoscope and explains how having both an electric and sound component can help physicians catch heart disease (and more) earlier

Sweden's Annoca announced a $46M raise last month to help move its first TCR-T program into the clinic for KRAS-driven pancreatic cancer. CEO Reagan Jarvis tells us about that work and more.

Xspray Pharma makes protein kinase inhibitors that are amorphous, and therefore more soluble than current products. Dasynoc, its version of dasatinib (Sprycel), is in front of FDA with an Oct 7 PDUFA

Pareto Securities Healthcare Conference: Egetis Therapeutics has a therapy for a rare disease called MCT8 deficiency that is approved by the EMA and has breakthrough therapy designation in the U.S.

Pareto Securities' Healthcare Conference: Cinclus Pharma is trying to user in the next generation of acid reflux medicines with, linaprazan glurate, a potassium-competitive acid blocker (P-CAB)

Pareto Securities' Healthcare Conference: Biotech Analyst Dan Akschuti shares his take on the the conference and the state of biotech, and highlights key companies to watch in the region

Pareto Securities' Healthcare Conference: Saniona has built expertise in the ion channel space, in addition to its own work, it has partnerships with Jazz, Acadia, and others

Pareto Securities' Healthcare Conference: BioArctic's CEO Gunilla Osswald highlights the company's brain transporter technology, the latest on Leqembi, and a Parkinson's program

Pareto Securities' Healthcare Conference: Guard Therapeutics will have a key P2b trial read for its kidney protecting therapy RCM-035 in the 4th quarter - CEO Tobias Agervald walks us through it

Pareto Securities' Healthcare Conference: BioInvent has recently optimized its pipeline to focus on two key programs - BI-1808, the anti-TNFR2 antibody, and BI-1206, an FcγRIIB inhibitor

Pareto Securities Healthcare Conference: Basilea is using its financial strength from two marketed products to develop its pipeline and acquire new products - it just received more BARDA funding today

Takeda's CEO Christophe Weber describes the company's landmark phase 3 data that was presented at World Sleep Congress this week for its first-in-class orexin agonist for treating narcolepsy type 1

Leaders of Brandon Capital, a seed and VC firm formed in Australia and with an office in the UK as well, discuss their $290 million sixth fund

Biotech veteran Harvey Berger was named Chairman & CEO of Arena BioWorks today - he describes how 'foraging to focusing' will be the name of the game

Stevenage, UK based NRG Therapeutics raised a $67M series B today to advance its aim to restore mitochondrial function and slow the progression of neurodegenerative diseases like Parkinson's and ALS

Fairtility has received FDA clearance on its AI-based embryo assessment tool for IVF, CHLOE Blast, that helps embryologists with embryo and oocyte assessments

N-Power Medicine launched what it is calling the 'Industry’s First Prospective External Control Arm Platform' for cancer trials - Mark Lee, CEO and a medical oncologist, explains why and how it works

Cytokinetics' CEO Robert Blum discusses the result of the MAPLE-HCM study of aficamten, and other learnings from the European Society of Cardiology Congress 2025

John Maraganore and Clive Meanwell are launching Corsera Health out of stealth - which, through a combo of predictive diagnostics and an RNAi targeting PCSK9 and angiotensinogen, aims extend lifespans

The CEO of Tennr, which raised a $101M series C earlier this summer, explains how the company's platform uses large language models to make the patient referral process to specialists more efficient

Stanford professor James Zou and his team created a virtual lab with AI scientists - they designed nanobodies for a COVID variant

William Blair Senior Biotech Analyst Andy Hsieh reacts to today's oral obesity data from Viking's VK2735 and recent data from Lilly's orforglipron

Celebrating the 2025 Nucleate Alumni Summit

After exiting stealth with $20 million two weeks ago, Orchestra Bio is out to help science entrepreneurs handle the dollars and cents management and long term planning that business requires

Biotech Direct: MassBio CEO Kendalle Burlin O'Connell and Seaport Therapeutics Founder & CEO Daphne Zohar discuss NIH funding, recent developments at FDA, and improving the public's view of science

IO Biotech CEO Mai-Britt Zocca discusses the phase 3 pivotal trial result of the cancer vaccine Cylembio in first line advanced melanoma - and the company's strategy ahead

Checking in on the progress of CAR-T for autoimmune conditions with the CEO of Kyverna - the company's first (and first for the field) registration intended trial will read in the first half of 2026

Bay Area based Nosis Bio is leveraging AI to get its gene silencers specifically to precise cell types - it recently announced a development candidate to tackle fibrosis

Checking in with Alector CEO Arnon Rosenthal ahead of a pivotal trial readout for latozinemab in frontotemporal dementia in the fourth quarter

IDEAYA Biosciences is at the forefront of precision oncology - we discuss the pipeline, including a key pivotal trial that will read out for Darovasertib by the end of the year

CytomX Therapeutics' years of work on its 'Probody' masking technology may be paying off at a time when there is growing focus on this approach - it presented key initial data on its EpCAM ADC in May

Maze Therapeutics, which had its IPO earlier this year, is using insights from genetics to develop small molecules - its most advanced program is for a genetic kidney disease

Astria Therapeutics licensed its HAE treatment, Navenibart, to Kaken Pharmaceutical for the Japanese market. It is a kallikrein inhibitor that is in phase 3, and is dosed up to every six months

AI News: While most AI in healthcare is aimed at helping physicians better diagnose and treat disease, CureWise is built for patients to help understand their conditions and ask the right questions

From Indianapolis: Serial entrepreneur Derek Small publicly launched a new neuroscience company with $90M earlier this summer, Syndeio Biosciences. He tells us about it and talks Indiana biotech.

From Indianapolis: Adipo Therapeutics is approaching the obesity space by trying to turn energy storing 'white' fat into energy burning 'brown' fat

The Indiana Biosciences Research Institute is a central hub for the biotech scene in Indiana - its CEO describes what it is all about, and the status of biotech here today

BiotechTV visits Indiana University School of Medicine's Stark Neurosciences Research Institute and discusses the latest in Alzheimer's research with its executive director, Bruce Lamb

Former NIH Director and Co-Founder of ModeX Therapeutics Elias Zerhouni shares his take on possible NIH cuts and the state of science in the United States, and working on multispecifics at his company

AI x Bio Summit: Proscia CEO David West describes how AI in pathology is not just helping pathologists find disease, but can also help get the right drug to the right patient

Monte Rosa Therapeutics' CEO Markus Warmuth updates us on the company's progress in developing molecular glue degraders

Abivax CEO Marc de Garidel discusses Obefazimod's phase 3 trial result in ulcerative colitis, and what is next for the company

AI x Bio Summit: Recursion's Chief R&D Officer & CCO Najat Khan describes how the company leverages AI - including in both the dry lab and the wet lab, and all through clinical trials

After receiving a CRL for its RP1 oncolytic immunotherapy yesterday, the CEO of Replimune walks us through the program's timeline and history, and what this might mean for its future

AI x Bio Summit: The CEO of Alto Neuroscience, which is working on precision medicine for neuroscience, talks about how the company is using AI and machine learning in its development programs

NYSE Strategist Eric Criscuolo shares his take on the markets and biotech sentiment

AI x Bio Summit: The Co-Founder and Head of Machine Learning at Dyno Therapeutics describes how his company is using AI to design better capsids

RBC's Healthcare Desk Strategist Chris McCarthy discusses biotech sentiment, and positioning around key events and catalysts that are upcoming

AI x Bio Summit: Nimbus Therapeutics' new CEO and head of R&D describe how AI is an isn't used in the company's R&D process

Metsera CEO Whit Bernard shares an update on the company's obesity programs, and comments on the state of the field post ADA

Cambridge, MA based Avalyn Pharma is developing a novel inhaled formulation of pirfenidone and other medicines for pulmonary fibrosis - it just raised a $100M (up round) series D financing

On a visit through London today, NodThera's CEO Dan Swisher discusses the company's brain-penetrant NLRP3 platform, including an asset that's in phase 2 for weight loss

Prime Medicine's new CEO Allan Reine walks us through the prime editing company's new focused pipeline

Kailera Therapeutics' partner Hengrui announced positive p3 results for its GLP1/GIP agonist in China - biotech veteran and Kailera CEO Ron Renaud walks us through the company's obesity space strategy

Southampton professor, and Curve Therapeutics' CSO, Ali Tavassoli describes the unique properties of cyclic peptides and why he believes Curve's cell-based method to drug discovery makes it different

Southampton, UK based Curve Therapeutics believes its mammalian cell-based 'Microcycle' platform is a better way to do drug discovery - lead programs from it target HIF-1/HIF-2 and ATIC

Checking in with MoonLake's CEO ahead of one of biotech's most closely watched trial readouts of the year - the phase 3 VELA program of sonelokimab in HS (due in Sept)

KalVista's CEO discusses today's FDA approval and commercial launch of Ekterly, the first oral therapy for treating hereditary angioedema (HAE) attacks

AI News: Singapore based Gero, a company focused on small molecules for aging conditions, launched ProtoBind-Diff, a model using amino acid sequences rather than structure models for discovery

Jones Research analyst Catherine Novack discusses Capricor's regulatory roller coaster, RNA editing, and more

ArsenalBio's Co-Founder & CEO Ken Drazan talks about engineering the next generation of T-cell therapies, including a clinical stage renal cell program that includes multiple features

Discussing hot button issues for biotech, and how they do or don't affect the mechanics of M&A, with one of the most experienced bankers in healthcare, Jefferies' Philip Ross

William Blair biotech analyst Andy Hsieh takes stock of the obesity space after attending the 2025 American Diabetes Association's (ADA's) 85th Scientific Sessions in Chicago

Checking in with the co-founders of Amylyx Pharmaceuticals, which now has one program in pivotal, another that may start soon, and earlier stage clinical programs that will have data this year

Oxford, UK based Pathios Therapeutics is targeting GPR65 for cancer, a signaling pathway that becomes active in the low pH tumor microenvironment and causes immunosuppression and high angiogenesis

Emeryville based Fauna Bio launched Fauna Brain, an AI platform that uses both internal and external data sets, and an analysis of the literature, to allow users to identify and score targets

The Co-Director of Cardiff University's Medicines Discovery Institute talks about the specialized work that happens here in neuroscience, cancer, and beyond

SV Health Investors Managing Partner Kate Bingham shares the firm's investment philosophy and gives her take on the current state of life sciences in the United Kingdom and beyond

AI News: Alameda based Infinimmune launched its GLIMPSE-1 antibody engineering platform that is based on a protein language model focused on native human antibody sequences

Draig Therapeutics launched from stealth today with a total of $140M investments to tackle neuropsych conditions. Co-Founder & Executive Chair Ruth McKernan tells the backstory and why she is excited

BIO International 2025: Sweden's Alligator has a phase three ready CD40 asset for pancreatic cancer and is looking for a partner to move it forward

BIO International 2025: The new CEO of Sweden's Hansa Biopharma discusses potential uses of the company's IgG busting drug, imlifidase, including for kidney transplant and along with gene therapy

BIO International 2025: Oppenheimer's Head of Healthcare Investment Banking, Michael Margolis, discusses biotech sentiment, M&A, and what it is like to raise money today

BIO International 2025: Perspective Therapeutics CEO Thijs Spoor describes why the company prefers radiopharmaceuticals with alpha-particles, and breaks down three main programs

BIO International 2025: CEO Paul Hastings discusses the progress Nkarta is making on its NK cell approach to autoimmune conditions

BIO International 2025: Germany's Aicuris, a company that focuses on helping immunocompromised patients, has breakthrough therapy designation for its HSV treatment that is in a pivotal

BIO International 2025: UroGen CEO Liz Barrett discusses last week's approval of ZUSDURI for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer

BIO International 2025: eGenesis CEO Mike Curtis discusses the case of the second patient who has received a transplant using the company's genetically engineered porcine kidney, and what is next

BIO International 2025: Stifel's Tim Opler comments on improvements in sentiment he is seeing for the biotech sector, and his take on hot button issues

BIO International 2025: Ocugen CEO Shankar Musunuri discusses the company's gene therapy platform for eye conditions - one of which is already in a pivotal, with another to start

EHA 2025: Arcellx CEO Rami Elghandour discusses the results presented today of the iMMagine-1 Study for the company's BCMA CAR-T

EHA 2025: The CEO of Ascentage Pharma, which had its U.S. IPO earlier this year, introduces us to the company and discusses BCR-ABL, Bcl-2, and EED targeting programs

EHA 2025: MaaT Pharma presented an update for its microbiome based treatment for GVHD, Xervyteg, which it has now filed for approval with the EMA

Microsoft's Chief Scientific Officer for Health and Life Sciences shares his take on how AI is changing healthcare today and what is possible in the future

EHA 2025: CEO Arthur Sands discusses Nurix Therapeutics' BTK degrader data, the development plan ahead, recent #AACR25 data regarding brain penetration, and activity in the autoimmune space

EHA 2025: CEO Jonathan Dickinson discusses Innate Pharma's NK cell engager platform (ANKET), recent ASCO data for Lacutamab, and other program updates

CLAIRITY BREAST, an AI platform that predicts five-year breast cancer risk from routine mammograms, became the first such AI tool to receive FDA authorization for breast cancer prediction

Nucleate UK held its "The Forum" event in London - where it brought together the biotech community for networking, education, and to celebrate companies that have been through its Activator program

AI News: Artera presented data at #ASCO25 showing that its AI platform can identify prostate cancer patients most likely to benefit (or not benefit) from added androgen receptor inhibitor therapy

Kymera Therapeutics' Founder & CEO Nello Mainolfi discusses the safety, degradation, and biomarker profile he sees in the company's STAT6 healthy volunteer data

ASCO 2025: PharmaMar presented data showing that the combo of Zepzelca and Tecentriq significantly improved survival as first-line maintenance therapy for extensive-stage small cell lung cancer

ASCO 2025: France based Transgene presented data for its personalized cancer vaccine in the adjuvant setting for HPV- head and neck cancer

ASCO 2025: Candel Therapeutics CEO Paul Peter Tak describes phase 3 prostate cancer data from the company's off-the-shelf, adeno delivered, cancer immunotherapy

ASCO 2025: Strand Therapeutics Co-Founder & CEO Jake Becraft discusses the clinical data presentation for the company's IL-12, self-replicating mRNA cancer immunotherapy

ASCO 2025: Allogene presented data today for a CD70 targeting allogeneic CAR-T against renal cell carcinoma, with a 31% response rate

ASCO 2025: The leaders of Daiichi-Sankyo discuss new data for the ADC ENHERTU in 1L HER2+ breast cancer and 2L HER2+ gastric cancer, plus new targets that are emerging

Deerfield Management Managing Partner James Flynn discusses a new $600M venture fund the firm has raised and describes how it will be invested, including into AI companies

ASCO 2025: Protagonist Therapeutics' CEO Dinesh Patel discusses the results of the phase 3 study of Rusfertide for polycythemia vera, plus a recap of recent ulcerative colitis data for its IL-23R

ASCO 2025: Bicara Therapeutics' CEO Claire Mazumdar discusses the company's EGFR x TGF-β data in head and neck cancer, and compares and contrasts it with a closely watched competitor

ASCO 2025: Legend Biotech's CEO Ying Huang discusses new CARVYKTI data at ASCO as well as early stage data for emerging CAR-T targets against solid tumors

ASCO 2025: Arcus Biosciences' CEO Terry Rosen discusses data for the HIF-2a inhibitor Casdatifan in combination with Cabozantinib in kidney cancer

ASCO 2025: Arvinas CEO John Houston discusses the phase 3 study result of the PROTAC Vepdegestrant in breast cancer, the first phase 3 readout of its kind for the field of protein degradation

ASCO 2025: Novocure today announced positive overall survival data for its tumor treating fields technology in hard to treat pancreatic cancer

ASCO 2025: Gilead Sciences' Chairman & CEO Dan O'Day discusses today's 'practice changing' data for Trodelvy in 1L triple-negative breast cancer, cell therapy, and more from the oncology pipeline

ASCO 2025: Instil Bio CEO Bronson Crouch discusses the company's PD1 x VEGF, and shares a quick take on this morning's competitor news

Pfizer Chairman & CEO Dr. Albert Bourla discusses the company's bets on cancer research, VEGF x PD1, #ASCO25 data, and hot button issues affecting the biopharma industry

Piper Sandler Senior Analyst David Amsellem reacts to today's Teva Innovation & Strategy Day and shares his take on the company's pipeline

At Teva's Innovation & Strategy Day in New York today, CEO Richard Francis discusses what 'Pivot to Growth' means for the company and offers takeaways from the presentation

Previewing top breast cancer and antibody-drug conjugate presentations to watch at this week's ASCO Annual Meeting with Dana-Farber's Paolo Tarantino

RBC Global Healthcare Conference: Desk Strategist Chris McCarthy shares how institutional investors have been affected by policy and macro factors, and how they have been positioning around catalysts

RBC Global Healthcare Conference: Senior Biotech Analyst Luca Issi shares his thoughts on the current state of gene and cell therapy

RBC Global Healthcare Conference: Korro Bio entered the clinic with its RNA editing platform in January and will have multiple cohorts of data in AATD later this year

RBC Global Healthcare Conference: With a phase 3 for its lead program scheduled to read in Q3 and mid-stage data for another program coming up this quarter, aTyr Pharma has pivotal months ahead

RBC Global Healthcare Conference: Ocular Therapeutix's Chairman & CEO Pravin Dugel provides an update on the progress of the pivotal studies for AXPAXLI in wet AMD

RBC Global Healthcare Conference: RBC's Brian Abrahams shares his take on biotech and offers advice for companies on how to navigate these times of change

RBC Global Healthcare Conference: Ahead of an important trial readout next month, Jeff Stein explains Cidara's unique approach to influenza and how it differs from vaccines

Stevenage, UK based TessellateBio recently signed a collaboration and licensing deal with Boehringer Ingelheim targeting tumors dependent on alternative lengthening of telomeres (ALT) for their growth

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk

ASGCT 2025: Dyno Therapeutics CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions

ASGCT 2025: Physicians and scientists raced to make a bespoke gene editing therapy for an infant who urgently needed one in months - a first hand account, and what this means for drug development

ASGCT 2025: Coave Therapeutics presented a late breaker showing a positive profile for its cerebrospinal fluid administered ligand-engineered AAV2-based capsid

Cambridge, UK based Alchemab Therapeutics last week signed a second collaboration with Eli Lilly worth up to $415M to license its IND ready program for ALS and other neurodegenerative diseases

ASGCT 2025: The Co-Founder of ProQR discusses the company's Axiomer RNA base editing technology - which will see a CTA filed this quarter and data by the end of the year

ASGCT 2025: Capsida Biotherapeutics is using its expertise in capsid design to develop gene therapies that are tissue specific, and in the case of the CNS, can be delivered via IV and crosses the BBB

ASGCT 2025: The co-founders of Circio describe the properties they believe make circular RNA a better, more durable medium for use in gene and cell therapies

Gene therapies expert TJ Cradick previews what to watch for at the 2025 ASGCT Annual Meeting in New Orleans

Inductive Bio raised a $25M series A last week to continue its work utilizing AI to help drug developers in discovery understand a small molecule's ADMET properties before it is synthesized

NewLimit raised a $130M series B round last week to advance its work using epigenetic reprogramming to improve cell function and thus aim to extend longevity

Biotech investor Christoph Broja of EQT Life Sciences discusses biotech in Europe and highlights portfolio companies Tubulis, Agomab Therapeutics, and PanTera

With a phase 3 trial for its PRAME cell therapy underway and a data update coming up at ASCO, Immatics is pushing to be a leader in TCR based cell therapies and T-cell engagers

Mosaic Therapeutics, which uses advanced computational methods and next-generation cancer models to design novel combination therapies, licensed an ERK1/2 and MDM2 inhibitor from Astex Pharmaceuticals

Cambridge, UK based Epitopia is helping Merck (MSD) discover tumor associated antigens from the non-coding regions of the genome using its CryptoMap platform

Munich based Tubulis is working on ADCs that it believes are more durable, potent, and homogenous than others on the market currently - it has signed partnerships with Gilead and Bristol

As the field builds on the initial success of PARP inhibitors, Artios Pharma is working on the next generation of DNA Damage Response (DDR)-based therapies - it just had clinical data on one at AACR

Munich based ITM Radiopharma is progressing towards a first NDA in the U.S. with a robust pipeline behind it - all the while making investments in isotope manufacturing that has slowed others

Munich based Ethris is developing a proprietary mRNA and lipid nanoparticle combination that is stable and allows for nasal administration or to be inhaled via nebulization

Swiss Biotech Day: Geneva based Light Chain Bioscience is developing bi-specifics that integrate two light chains into its structure with the goal of having a more native format

Swiss Biotech Day: Milan based Genenta Science recently raised €20 million from a government investment fund as it takes its cell therapy into the clinic in renal cell carcinoma

Swiss Biotech Day: Lausanne based Tigen Pharma is building out decentralized CAR-T manufacturing capabilities with global partners - it already has a program with Memorial Sloan Kettering

Swiss Biotech Day: Lausanne based Vandria is focused on rejuvenating cells in age-related and chronic disease by inducing the removal of damaged mitochondria

Swiss Biotech Day: Basel based BioVersys successfully completed an approximately CHF 80 million IPO in February to advance its work in antimicrobial resistance

Swiss Biotech Day: Zurich based LimmaTech Biologics is developing vaccines against antimicrobial resistant pathogens

Swiss Biotech Day: Basel based Nouscom presented data at AACR last week on its cancer vaccine that is meant to lower the risk of Lynch Syndrome carriers from having future cancers

Swiss Biotech Day: Molecular Partners' CEO and Swiss Biotech Association president Patrick Amstutz shares his take on biotech and previews what to expect from his U.S. listed company in 2025

At a reception on the eve of Swiss Biotech Day, Swiss Biotech Association CEO Michael Altorfer introduces us to the conference and shares his thoughts on the state of biotech and global collaboration

Biotech investor Thilo Schroeder of Nextech Invest shares his take on biotech and discusses portfolio companies Revolution Medicines, Tubulis, and Circle Pharma

VERAXA Biotech, which is part of Switzerland's Xlife Sciences incubator, will be going public in the U.S. via a SPAC in Q4 of this year. The company uses an AND-gating technology for TCEs and ADCs.

Zurich based CUTISS is developing a personalized tissue therapy that enables on-demand production of living skin for surgeries

London based Baseimmune shows BiotechTV the new space it moved into in LBIC's Apex Building in Kings Cross where it will use its AI platform to discover and develop new vaccines

Creyon Bio today announced a collaboration to help Lilly use its AI-powered oligo engineering platform and aptamer-based delivery approach to discover and develop therapies in a range of diseases

London based Laverock shows BiotechTV the new space it moved into in LBIC's Apex Building in Kings Cross where it will be doing its work on programmable gene silencing

The London BioScience Innovation Centre (LBIC) today launched its new Apex Building lab space facility for biotech companies in the heart of the Kings Cross Knowledge Quarter

Talking chromatin regulation at Foghorn Therapeutics - whose partner Lilly will have preclinical data at AACR highlighting how the lead SMARCA2 program could do in combinations with other therapies

Epicrispr Biotechnologies' CEO Amber Salzman describes how her company will be utilizing AI muscle analysis in its clinical study for facioscapulohumeral muscular dystrophy

Lexeo Therapeutics' CEO Nolan Townsend highlights recent FA cardiomyopathy data and the path ahead in that indication. Plus, the latest on ACM, and more

Metsera's CEO Whit Bernard on the obesity space, including GLP-1s, amylin analogs, and how the company is also developing both as oral peptides

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

As federal funding for cancer research has been jeopardized at NIH and academia, Parker Institute for Cancer Immunotherapy is one private institution ready to step up and broaden its impact

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Marea Therapeutics today announced acceptance of a late-breaker at #EASCongress2025 for its ANGPTL4 inhibitor - believed to be the first ever clinical data presented for this lipid lowering target

After switching to a new GalNAc-LNP delivery vehicle a year ago, Verve Therapeutics today announced the initial safety and efficacy data from its VERVE-102 PCSK9 base editor

Mount Sinai has embraced AI as a drug discovery tool by launching this month its new AI Small Molecule Drug Discovery Center - Professor Avner Schlessinger tells us why

Jones Healthcare & Technology Innovation Conference: Jones Research analysts Soumit Roy and Justin Walsh share their take on biotech and comment on companies they cover

Jones Healthcare & Technology Innovation Conference: Pharvaris is developing oral bradykinin B2 receptor inhibitors for HEA - with a first pivotal scheduled to read in less than a year

Jones Healthcare & Technology Innovation Conference: Biotech veteran David Hung on his company Nuvation Bio, which has an FDA decision for its ROS1 scheduled for June

Jones Healthcare & Technology Innovation Conference: Wave CEO Paul Bolno discusses recent DMD data and regulatory feedback, and shares updates on alpha-1 antitrypsin, obesity, and Huntington's

Jones Healthcare & Technology Innovation Conference: The CIO of XOMA Royalty describes the inner workings of the royalty business, and also how to help with biotech's negative enterprise problem

Jones Healthcare & Technology Innovation Conference: Trevi Therapeutics CEO Jennifer Good describes recent positive data in refractory chronic cough and previews upcoming IPF data

Jones Healthcare & Technology Innovation Conference: Jones Research analysts Catherine Novack and Debanjana Chatterjee share their take on biotech and comment on companies they cover

Analyst Thursdays: Stifel's Alex Thompson updates us on the latest news and upcoming catalysts in the I&I space

Anglo Nordic Life Science Conference: The CEO of Cure Parkinson's talks about their work, and participating in the International Linked Clinical Trials Initiative

Anglo Nordic Life Science Conference: Denmark based Synklino is developing a fusion protein that targets US28 for CMV infections from transplants

On the heels of raising a $65M series B, the CEO of Flagship's Ampersand Biomedicines describes the company's precision medicine platform, and gives updates on partnering and R&D progress

BioTrinity 2025: With a novel E3 ubiquitin ligase (TRIM21) for protein degradation, Cambridge, UK based TRIMTECH Therapeutics recently raised a $31 million seed round

Vida Ventures named Matt Cohen and Brian Goodman new Managing Directors today. BiotechTV caught up with Brian in Vida's Boston office

After a $93M series B, Character Bio's CEO Cheng Zhang describes how the company has built a proprietary database to reclassify AMD patients into genetic subgroups to optimize trial patient selection

BioTrinity 2025: AlveoGene Executive Chair David Hipkiss describes the company's unique inhaled gene therapy platform that fuses a Sendai virus and Lentivirus, and can be redosed

Miami based Galatea Bio raised $25M today to expand its 'Galatea Global Biobank', an initiative to sequence 10 million participants worldwide, with a focus on individuals of non-European ancestry

State of Possible: Winner of the MassBioDrive Startup of the Year Award last year, the Co-Founder and CEO of Eascra Biotech describes developing nanoparticles as a delivery vehicle for therapies

State of Possible: Atlas Venture's Bruce Booth shares his take on the current state of biotech and what it takes to get through difficult times for the industry as an investor and for companies

State of Possible: On the one-year anniversary of the spin-out of Seaport Therapeutics, Daphne Zohar describes the Glyph platform that powers it, and her thoughts on running depression trials

State of Possible: Beam Therapeutics' CEO John Evans discusses the company's recent alpha-1 antitrypsin deficiency data, what's ahead for sickle cell disease, and the current environment for biotech

State of Possible: Cigall Kadoch discusses her pioneering work in chromatin regulation that has led to Foghorn Therapeutics

State of Possible: Kymera Therapeutics Founder and CEO Nello Mainolfi talks protein degradation, his take on recent industry data, and updates on the company's programs, including a new one to come

State of Possible: Massachusetts Governor Maura Healey discusses keeping the state on top in life sciences, global competition, and more

State of Possible: Strand Therapeutics' Co-Founder & CEO Jake Becraft talks mRNA and getting into the clinic with the company's first program

At an R&D event hosted by the company in Kendall Square today, Alloy Therapeutics' CEO Errik Anderson talked the latest in science regarding bispecifics, TCR mimics, genetic medicines, and more

Oxford, UK based Greywolf Therapeutics is pursuing cancer and autoimmune indications by attempting to target T-cells at their first signal of activation - an approach the company leads the field on

Brainomix, an Oxford, UK based company that uses AI to help front line physicians analyze CT scans for stroke damage and interstitial lung disease, announced an $18M series C raise today

AnaptysBio's CEO discusses recent 12 week RA data from the company's PD-1 depleter and agonist, rosnilimab, and previews other upcoming catalysts

Analyst Tuesdays: Mizuho Senior Analyst Graig Suvannavejh shares his take on the difficult biotech environment and discusses upcoming clinical trail catalysts for companies he covers

The co-founders of Vevo Therapeutics describe the Arc Virtual Cell Atlas, a large single cell atlas made publicly available with Arc Institute that now includes Vevo's Tahoe-100M database

From struggling with sickle cell disease to climbing mountains - a firsthand account of how gene therapy has been life changing

Bonum Therapeutics aims to lower the toxicity of medicines such as cytokines by regulating them via a unique sensor domain that is designed to activate a therapeutic at its target

Alta Partners' Managing Director Bob More shares his take on biotech and his philosophy of investing in people - from the Timmerman Report 10th Anniversary Celebration in Seattle

Congratulations to Luke Timmerman on 10 years of Timmerman Report. We salute you!

Tour of Scotland: Glasgow based EnteroBiotix is developing microbiome based treatments using a 'full ecosystem' of strains you would expect to see in a healthy microbiome

Tour of Scotland: Scotland's Chief Scientist (Health) describes how new technologies are being embraced in the NHS, and why Scotland is a good place for global companies to run clinical trials

HumanX: Generate Biomedicines' CEO Mike Nally describes how he sees AI going from improvements in optimization to drugging the undruggable

Tour of Scotland: St. Andrews based Pneumagen aims to prevent viral respiratory infections with an intra-nasally delivered platform that harnesses glycan targeted Carbohydrate Binding Module domains

Tour of Scotland: Dundee based Glen Clova Scientific is using virus like particles to lower levels of cytokines in patients experiencing chronic inflammatory conditions

Tour of Scotland: Mark Cook, Co-Chair of Life Sciences Scotland describes the importance of life sciences to the area and what the government and industry are doing to support it

Tour of Scotland: Glasgow based Mironid is developing a small molecule to directly target aberrantly high cAMP that causes Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Tour of Scotland: Vicki Hazley, Associate Director of The Scottish National Investment Bank, discusses how The Bank invests in life sciences

Professor Pieter Cullis and Jay Kulkarni, co-founders of NanoVation Therapeutics, discusses the next generation of lipid nanoparticle delivery

Tour of Scotland: Edinburgh based Trogenix is developing an AAV based gene therapy platform for cancer that is designed to deliver combination immune payloads to the tumor

Tour of Scotland: A leading investor who is focused on life sciences in Scotland shares his thoughts on the innovation happening in the area

Acuitas Therapeutics is a pioneer in developing lipid nanoparticals, and already has seen two approved products: ONPATTRO and the Pfizer/BioNTech mRNA vaccine

Tour of Scotland: Edinburgh based Cumulus Oncology has built a hub and spoke model of creating multiple spin-out companies - it already has three disclosed assets

Tour of Scotland: Outrun Therapeutics is aiming to create a new category of therapeutics by stabilizing proteins via drugging E3 ligases

Tour of Scotland: Tay Therapeutics is a product of University of Dundee's Drug Discovery Unit, and is working on small molecules - including a topical pan-BET that is in phase 2

Tour of Scotland: University of Dundee has established a world-class Centre for Protein Degradation, one of the hottest emerging modalities in biotech

Tour of Scotland: The Head of Business Development at University of Dundee's Drug Discovery Unit talks about how the university helps biopharma companies translate science into medicines

Tour of Scotland: Sir Michael Ferguson introduces the work in life sciences that has built up at The University of Dundee and the specialized centers that have come from it

A study published in JMIR today showed that Limbic's GenAI-powered chatbot elevated the standard of care for mental health patients in the UK’s National Health Service (NHS)

Analyst Thursdays: William Blair Senior Analyst Andy Hsieh talks about his new obesity sector report and the companies he initiated

On Rare Disease Day, Ultragenyx's Head of Gene Therapy Research explains the company's Rare Disease Bootcamp that helps families navigate drug development, and he also talks gene therapy science

Cambridge, UK based Amphista Therapeutics is developing a new generation of targeted protein degradation therapies that do not rely on cereblon or VHL

Cambridge, UK based Ignota Labs raised a $6.9M seed funding today and will use AI to understand why otherwise promising therapies have failed on tox by surprise and then to reengineer them

With unique license agreements in place with local universities and an additional $260M recently raised, Cambridge, UK based Apollo Therapeutics is building out a substantial pipeline

From Boston: Stifel Senior Analyst Paul Matteis talks about the orexin class of wakefulness medicines in development, and comments on recent news from companies he covers

Australia based Aravax, which is using a peptide based approach to food allergy treatments with the goal of avoiding inflammation, is building out late stage manufacturing capabilities in Oxford, UK

Oxford based Theolytics is leveraging a library of 100M variants of adenoviruses for a bottom up approach to oncolytic virus cancer drug development

With three approved products and filings for more over the near term, Axsome's CEO describes the scale and reach this company is building in the CNS space

Stoke Therapeutics' CEO Ed Kaye discusses today's partnership news with Biogen on Zorevunersen for the treatment of Dravet syndrome

The CEO of Solid Biosciences discusses today's data release of the company's microdystrophin gene therapy candidate for Duchenne muscular dystrophy

Paula Brown Stafford, CEO of the global CRO Allucent, discusses how the company is purpose built to partner with mid-to-small sized biopharma companies on their success

Welcoming Ryan Flinn as BiotechTV's new 'AI in Biotech' contributor

Oppenheimer's Head of Healthcare Investment Banking shares his take on 2025 and highlights M&A, IPOs, and the ability of companies to raise money this year

John Maraganore shares his take on biotech in 2025 and discusses the science behind his recently launched RNAi company, City Therapeutics

Mizuho Senior Biotech Analyst Salim Syed shares his take on 2025 and key catalysts from companies he covers

Rapport Therapeutics has derived what it believes is 'unprecedented' early efficacy for its precision neuroscience treatment in focal onset seizures - its confidence comes from a unique trial design